Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2026)

Atara Biotherapeutics (ATRA) has reported Gross Margin for 5 consecutive years, with 69.68% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 2717.0% year-over-year to 69.68%; the trailing twelve-month figure through Jun 2026 stood at 91.38% (up 1014.0% YoY), and the FY2025 full-year result was 82.44%, down 127.0% from the prior year.
• Gross Margin slipped to 69.68% in Q2 2026 per ATRA's latest filing, from 75.97% in the prior quarter.
• Across five years, Gross Margin topped out at 100.0% in Q1 2022 and bottomed at 202.51% in Q2 2023.
• Historically, Gross Margin has averaged 62.89% across 5 years, with a median of 83.11% in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Margin tumbled 30251 bps in 2023, then soared 28635 bps in 2024.
• Over 5 years, Gross Margin stood at 100.0% in 2022, then sank by 74 bps to 25.68% in 2023, then surged by 209 bps to 79.25% in 2024, then rose by 18 bps to 93.48% in 2025, then retreated by 25 bps to 69.68% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 69.68%, 75.97%, and 93.48% for Q2 2026, Q1 2026, and Q4 2025 respectively.